Bavarian Nordic and Oxford BioMedica settle MVA-BN dispute

29-Jan-2010

Bavarian Nordic of Denmark and UK-based Oxford BioMedica have reached a settlement ending the legal disputes between the two companies in the US District Court for Southern California on matters relating to Modified Vaccinia Ankara (MVA-BN).

Bavarian Nordic of Denmark and UK-based Oxford BioMedica have reached a settlement ending the legal disputes between the two companies in the US District Court for Southern California on matters relating to Modified Vaccinia Ankara (MVA-BN).

Under the settlement, Bavarian Nordic will grant a licence to its MVA-BN patents in return for Oxford BioMedica making milestone payments and royalties.

Oxford BioMedica will grant Bavarian Nordic a licence to its heterologous prime-boost patents in return for Bavarian Nordic making milestone payments and royalties and a sub-licence under poxvirus patents licensed to Oxford BioMedica by Sanofi-aventis.

Oxford Medica has agreed to withdraw all pending litigation and all oppositions filed at the European Patent Office.

In addition both companies have agreed to initiate business discussions concerning a possible future collaboration based on each company's expertise in poxvirus vaccines and Bavarian Nordic's commercial manufacturing capability.

In a joint statement, John Dawson ceo of Oxford BioMedica and Bavarian Nordic ceo Anders Hedegaard said: "This settlement brings to an end the legal disputes between the two companies and provides a basis for both companies to progress their respective vaccine businesses."




Companies